GLP-1 Overview

Glucagon-like peptide-1 (GLP-1) is an incretin composed of 30 amino acids, primarily secreted by L-cells in the gut. It acts on the GLP-1 receptor (GLP-1R) and stimulates insulin secretion while inhibiting glucagon secretion in a glucose-concentration-dependent manner. It also slows gastric emptying and gastrointestinal secretion and reduces food intake, thereby achieving blood sugar reduction and weight control [James G. Boyle et al., (2018) Clin Sci (Lond)].

GLP-1 receptor agonists, or analogs, mimic these beneficial actions in the treatment of type 2 diabetes, enhancing glycemic control and often supporting weight loss.


GLP-1 Significance in Research and Therapeutics

Due to its beneficial effects on glucose control and potential for weight loss, GLP-1 and its analogs have become a focus for the development of therapies for type 2 diabetes and obesity.

GLP-1 receptor agonists, which are synthetic versions of the hormone, mimic the action of natural GLP-1 and have been approved for the treatment of type 2 diabetes. These medications not only help to improve glycemic control but also have been shown to have cardiovascular benefits in some patients.
Research continues to explore the broader therapeutic potential of GLP-1, including its effects on the cardiovascular system, brain function, and its potential role in the treatment of conditions beyond type 2 diabetes, such as Parkinson's disease and Alzheimer's disease. The understanding of GLP-1 and its physiological functions has significantly advanced our approach to managing conditions related to glucose metabolism and obesity.

Advancements in GLP-1 Therapy: Specialized Peptide Solutions

In the advancement of GLP-1 therapies, researchers employ fatty acid modification and Fc fusion protein techniques to enhance the effectiveness of GLP-1 receptor agonists. Recognizing the limitations of natural GLP-1's brief half-life, GenScript specializes in providing high-quality peptides that are essential for these sophisticated modifications.

To date, more than a dozen GLP-1 drugs have been launched globally. To better accelerate your GLP-1 new drug research and development, GenScript is now offering GLP-1 Receptor Agonist Services.

Read More about GenScript GLP-1 capability in the GenScript successful case section.

Need help from an expert?


One-Stop Service

From early drug screening, process development to cGMP production

Diversified Solutions

Robust modification techniques including advanced conjugation services with small-molecule drugs

Regulatory Compliance CMC Service

Streamlining GLP-1 analogs development and registration with comprehensive CMC services

How GenScript can support your GLP-1RA Drug Discovery

From Drug Discovery to Support for Clinical Trials

From Drug Discovery to Support for Clinical Trials
1 Drug Screening
  • > 20+ years of experience in peptide synthesis, we can deliver high-quality target sequences with a short turnaround time.
  • Possessing side-chain and non-natural amino acids perfectly matching the characteristics of the GLP-1 sequence.
  • Various modificationmethods for GLP-1, such as long-chain modification, halogenation, thiolation, biotinylation, and special amino acid modification, etc.
  • High success rate in synthesizing target segments with high hydrophobicity.
  • Production of bulk pharmacology and toxicology samples, preparation of APIs for formulation development.
  • Provide process development, quality studies (impurities studies, process validation, transfer), and scale-up services for clients on GLP-1 generic drugs.
  • Production of APIs for clinical, development and validation of analytical methods, and stability studies.
3 Regulatory Support
  • The regulatory team has extensive experience in the application process.
  • Regulatory support spans the whole drug lifecycle (Pre-IND, IND, NDA).
  • Compiling and technical review of CMC submission documents (FDA/EMA/NMPA/DMF).
  • Dedicated RA personnel providing one-to-one service.
  • GenScript has completed the writing of 6 IND-CMCs and received approval from CDE; provides CMC guidance and compliance analysis in accordance with FDA/EMA/NMPA regulations.
4 Clinical & Commercialization
  • Owns a 3,000 m² cGMP facility to meet cGMP requirements for clinical sample production.
  • cGMP delivery case support.
  • A brand new commercial production base, covering an area of 50,000 m², with 5 commercial production lines, coming up soon, supporting the entire lifecycle of GLP-1 from drug development to commercialization.

GenScript Successful Case

GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs!

Get in Touch with GenScript
GLP-1 Receptor
Agonist Service

Get in Touchwith GenScript GLP-1 Receptor Agonist Service
Please enter a valid first name.
Please enter a valid last name.
Please enter a valid email name.
Please select a valid industry.
Please select a valid country.
Please enter a valid Zipcode.
Please enter a valid institution/company.
Please enter a message in the textarea.



Do you like the current new website?